Living Drug Fights Diabetes Autonomously

A groundbreaking engineered oral probiotic, dubbed GIFT, has been developed by East China Normal University researchers for diabetes treatment. This living drug functions as an "intelligent virtual organ" within the intestine, utilizing synthetic biology to continuously monitor blood glucose levels. It responds to fluctuations by autonomously secreting hormones that lower blood sugar, providing on-demand therapeutic dosing.

This novel "sense-and-respond" platform represents a paradigm shift from traditional passive diabetes management, such as injections and medications. The GIFT probiotic enables "oral implantation and autonomous regulation," achieving a closed-loop control system for blood glucose. This innovation offers a safer, gentler, and more physiologically aligned treatment strategy for the hundreds of millions globally affected by diabetes.

The research, published in Nature on August 12, highlights the probiotic's advantages over cell-based therapies and other engineered bacteria. It avoids transplantation complexities and immunogenicity risks, while offering superior stability and safety. This development positions China at the forefront of smart living drugs and precision metabolic disease treatment.